Background The Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly and Drugs/alcohol (HAS-BLED) score is a validated bleeding risk prediction tool in patients with atrial fibrillation taking oral anticoagulation. Its predictive value in patients with atrial fibrillation undergoing percutaneous coronary intervention receiving combination of anticoagulation and antiplatelet therapy is unknown. This retrospective cohort study sought to validate the accuracy of HAS-BLED score in predicting the bleeding risk in patients with atrial fibrillation who underwent percutaneous coronary intervention receiving both anticoagulation and dual antiplatelet therapy. Method We calculated HAS-BLED score in 186 patients with AF undergoing coronary stenting and assessed the incidence of bleeding events defined by the International Society on Thrombosis and Hemostasis (ISTH) bleeding scale. Results The mean age of the study was 72 The proportion of male to female was 2.93: 1 Using a HAS-BLED cut off of ≥3, a significantly higher incidence of bleeding was detected in the high HAS-BLED compared to the low HAS-BLED cohort. Such difference of bleeding incidence remained significant in the triple therapy subgroup whereas it became statistically insignificant in the dual-antiplatelet subgroup. The predictive performance was modest (AUC 0.673, 95% CI, 0.535 – 0.811, p = 0.028). Conclusion HAS-BLED score is a simple and useful tool to predict bleeding risk in group of AF patients who require triple therapy after percutaneous coronary intervention.
Luk Yin Cheung Adrian, Chan Chi Lin Jaclyn, The Utility Of HAS-BLED Score In Predicting The Bleeding Risk Of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention Receiving Anticoagulation And Dual Anti-platelet Therapy: A Single Center Retrospective Cohort Study Journal of the Hong Kong College of Cardiology 2022;29(2):75-84 https://doi.org/10.55503/2790-6744.1211
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.